Tecentriq + Abraxane reduced risk of disease worsening, death in triple negative breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Genentech, a member of the Roche Group, announced that phase III IMpassion130 study met its co-primary endpoint of progression free survival.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Login